Table 4.

Cox model for TGFB1 and TGFBR1 polymorphisms and outcome in patients with muscle invasive bladder tumors.

SNP	Cases	Progression†					Disease-specific mortality‡
		N	HR	95%CI	p-LRT	p-trend	N	HR	95%CI	p-LRT	p-trend
TGFB1
rs1982073					0.931	0.796				0.533	0.718
TT	78	41	1.00	Ref			33	1.00	Ref
CT	116	65	1.09	0.69–1.71			49	0.89	0.56–1.39
CC	35	17	1.05	0.56–1.98			15	1.26	0.67–2.35
rs1800472					0.059	NA				0.073	NA
CC	218	113	1.00	Ref			88	1.00	Ref
CT	16	12	2.02	1.03–3.97			11	1.90	0.99–3.65
TT	-	0	NA	NA			0	NA	NA
rs1800471					0.102	NA				0.080	NA
GG	215	119	1.00	Ref			96	1.00	Ref
CG	22	7	0.46	0.20–1.06			4	0.40	0.15–1.11
CC	1	0	NA	NA			0	NA	NA
TGFBR1
rs868					0.531	0.341				0.013	0.003
AA	134	67	1.00	Ref			52	1.00	Ref
AG	81	44	1.29	0.83–2.03			35	1.85	1.15–2.97
GG	10	6	1.16	0.44–3.03			5	3.00	1.15–7.82
rs334358					0.801	0.547				0.032	0.009
GG	137	70	1.00	Ref			54	1.00	Ref
GT	80	42	1.16	0.74–1.82			34	1.67	1.05–2.68
TT	10	6	1.13	0.43–2.95			5	2.83	1.09–7.34
rs928180					0.259	0.259				0.813	-
AA	191	99	1.00	Ref			77	1.00	Ref
AG	36	19	1.39	0.80–2.41			16	1.07	0.61–1.87
GG	0	0	NA	NA			0	NA	NA
TGFBR1 exon 1					0.752	NA				0.943	NA
*9A/*9A	165	86	1.00	Ref			81	1.00	Ref
*6A/*9A	41	21	1.09	0.65–1.81			21	1.02	0.61–1.69
*6A/*6A	0	0	NA	NA			0	NA	NA

^†Adjusted for stage, localization, metastasis and treatment

^‡Adjusted for age, stage, localization and metastasis

NA, not applicable